Chronic coronary syndrome (CCS) represents a major challenge for physicians, particularly in the context of an increasing aging population. Additionally, CCS is often underestimated and under-recognised, particularly in female patients. As patients are frequently affected by several chronic comorbidities requiring polypharmacy, this can have a negative impact on patients' adherence to treatment. To overcome this barrier, single-pill combination (SPC), or fixed-dose combination, therapies are already widely used in the management of conditions such as hypertension, dyslipidaemia, and diabetes mellitus. The use of SPC anti-anginal therapy deserves careful consideration, as it has the potential to substantially improve treatment adherence and clinical outcomes, along with reducing the failure of pharmacological treatment before considering other interventions in patients with CCS.
Single-pill combination in the management of chronic coronary syndromes: A strategy to improve treatment adherence and patient outcomes? / F.J. Pinto, M.F. Piepoli, R. Ferrari, K. Tsioufis, G.M.C. Rosano, A. Nedoshivin, J.C. Kaski. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 1874-1754. - 384:(2023 Aug 01), pp. 10-17. [10.1016/j.ijcard.2023.04.046]
Single-pill combination in the management of chronic coronary syndromes: A strategy to improve treatment adherence and patient outcomes?
M.F. PiepoliSecondo
;R. Ferrari;
2023
Abstract
Chronic coronary syndrome (CCS) represents a major challenge for physicians, particularly in the context of an increasing aging population. Additionally, CCS is often underestimated and under-recognised, particularly in female patients. As patients are frequently affected by several chronic comorbidities requiring polypharmacy, this can have a negative impact on patients' adherence to treatment. To overcome this barrier, single-pill combination (SPC), or fixed-dose combination, therapies are already widely used in the management of conditions such as hypertension, dyslipidaemia, and diabetes mellitus. The use of SPC anti-anginal therapy deserves careful consideration, as it has the potential to substantially improve treatment adherence and clinical outcomes, along with reducing the failure of pharmacological treatment before considering other interventions in patients with CCS.File | Dimensione | Formato | |
---|---|---|---|
Pinto_IJC.pdf
accesso aperto
Descrizione: Review
Tipologia:
Publisher's version/PDF
Dimensione
505.88 kB
Formato
Adobe PDF
|
505.88 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.